The Emmes Company

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, The Emmes Company sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

The Emmes Company: 11 sponsored US clinical trials, none currently recruiting.

The Emmes Company sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Intra-abdominal Infection, with 1 trials.

Top-decile sponsor footprint

The Emmes Company ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED

Mitochondrial Video Assessment Source Material Study

NCT06180421
COMPLETED

Duchenne Muscular Dystrophy Video Assessment Registry

NCT05712447
TERMINATED

Limb-Girdle Video Assessment

NCT05528757
COMPLETED

Angelman Syndrome Video Assessment (ASVA) Source Material Study

NCT05637697
COMPLETED Phase 1

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

NCT03981549
COMPLETED Phase 3

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

NCT01969708
COMPLETED Phase 1

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

NCT00621192
TERMINATED Phase 2

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

NCT00393380
COMPLETED Phase 2

Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room

NCT00135668
COMPLETED Phase 3

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

NCT00105027
COMPLETED Phase 2

Lorazepam Sedation for Critically Ill Children

NCT00109395

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 2

Therapeutic Areas

Intra-abdominal Infection 1
Central Retinal Vein Occlusion 1
Necrotizing Enterocolitis 1
Duchenne Muscular Dystrophy 1

How the The Emmes Company early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 9 completed (82%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Intra-abdominal Infection (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

The Emmes Company: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

The Emmes Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share The Emmes CompanyAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
The Emmes Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

The Emmes Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this The Emmes Company page

11 registered trials is a research-attention snapshot, not an endorsement of The Emmes Company or any single study.

  • None of The Emmes Company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Intra-abdominal Infection is the condition The Emmes Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Intra-abdominal Infection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

The Emmes Company pipeline card: 11 registered trials from official public datasets.Report a data error.